Article Information
History
- October 28, 2021.
Article Versions
- Version 1 (September 16, 2021 - 13:19).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Paul M McKeigue1,6,*,
- David A McAllister2,6,
- Chris Robertson3,6,
- Sharon Hutchinson4,6,
- Stuart McGurnaghan5,
- Diane Stockton6,
- Helen M Colhoun5,6,
- for the PHS COVID-19 Epidemiology and Research Cell6
- 1Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, Scotland
- 2Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ
- 3Department of Mathematics and Statistics, University of Strathclyde, 16 Richmond Street, Glasgow G1 1XQ
- 4School of Health and Life Sciences, Glasgow Caledonian University. SH - Professor of Epidemiology and Population Health
- 5Institute of Genetics and Cancer, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, Edinburgh EH4 2XUC, Scotland
- 6Public Health Scotland, Meridian Court, 5 Cadogan Street, Glasgow G2 6QE
- ↵*Corresponding author: paul.mckeigue{at}ed.ac.uk
Posted October 28, 2021.
Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study
